Vertaling van "for bupropion sustained-release " (Nederlands → Frans) :

12. Jamerson BD, Nides M, Jorenby DE, Donahue R, Garrett P, Johnston JA, et al. Lateterm smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo.
12. Jamerson BD, Nides M, Jorenby DE, Donahue R, Garrett P, Johnston JA, et al. Lateterm smoking cessation despite initial failure: an evaluation of Bupropion sustained release, nicotine patch, combination therapy, and placebo.

40. Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey S et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial.
40. Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey S et al. Effectiveness of Bupropion sustained release for smoking cessation in a health care setting: a randomized trial.

A prospective safety surveillance study for bupropion sustained-release in the treatment of depression.
A prospective safety surveillance study for Bupropion sustained-release in the treatment of depression.

13. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained release bupropion, a nicotine patch or both for smoking cessation.
13. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained release Bupropion, a nicotine patch or both for smoking cessation.

39. Hatsukami DK, Rennard S, Patel MK, Kotlyar M, Malcolm R, Nides MA et al. Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking.
39. Hatsukami DK, Rennard S, Patel MK, Kotlyar M, Malcolm R, Nides MA et al. Effects of sustained-release Bupropion among persons interested in reducing but not quitting smoking.

De veiligheid en werkzaamheid van Decapeptyl Sustained Release 22,5 mg werden niet onderzocht bij pasgeborenen, zuigelingen, kinderen en adolescenten. Decapeptyl Sustained Release 22,5 mg is daarom niet aangewezen voor gebruik bij deze groepen.
L’innocuité et l’efficacité de Decapeptyl Sustained Release 22,5 mg n’ont pas été établies chez le nouveau-né, le nourrisson, l’enfant et l’adolescent, c’est pourquoi Decapeptyl Sustained Release 22,5 mg n’est pas indiqué dans ces populations.

The only adverse events which occur significantly more with bupropion slow release than with placebo are insomnia and dry mouth 2; 3 .
The only adverse events which occur significantly more with Bupropion slow release than with placebo are insomnia and dry mouth 2; 3 .

During the use of bupropion immediate release (IR) at dosages higher than 300 mg per day, there is an increased risk of seizures 10 .
During the use of Bupropion immediate release (IR) at dosages higher than 300 mg per day, there is an increased risk of seizures 10 .

Decapeptyl SR (Sustained Release) bevat triptoreline, vergelijkbaar met een hormoon dat Gonadotropine Releasing Hormoon (GnRH-analoog) heet.
Decapeptyl SR (Sustained Release) contient de la triptoréline, qui est semblable à une hormone appelée l’hormone entraînant la libération de gonadotrophines (analogue de la GnRH).

L. Allan et al.: Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain.
L. Allan et al. : Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain.